The latest biotech news - Labiotech.eu

Home News and Trends Page 274

Latest Posts

microbial resistance header

News and Trends 13 Dec 2016

How Will Biotech Overcome the Huge Challenges of Microbial Resistance?

The emergence of multi-drug resistant pathogens is alarming the scientific community since their growth is increasing at an incredibly fast pace. We gathered a group of experts to discuss how biotech is addressing this pressing concern and what the next big thing will be in the field of antimicrobial resistance. Achim Plum, CCO of Curetis, highlighted that […]

December 13, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Yuval Helfman

News and Trends 13 Dec 2016

European Pharma closes 2016 by launching new Biotech Startups

Big pharma is already head on starting 2017 with a bang. Pfizer and Bayer are launching US-based startups in oncolytic virus and stem cell therapies. Pharma is wrapping up 2016 by investing in a pair of new ventures. Bayer and Versant have invested $225M to launch BlueRock Therapeutics, which will focus on CNS and cardiovascular diseases. This comes […]

December 13, 2016 - 2 minutesmins - By Evelyn Warner

photowind

News and Trends 12 Dec 2016

French Biotech Puts a New Lyme Disease Vaccine on the Horizon

There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva might have a vaccine to stem the tide. Valneva, a commercial-stage biotech based in Lyon, France, has just received clearance from the FDA and its European counterpart to begin clinical trials for its experimental Lyme Disease […]

December 12, 2016 - 2 minutesmins - By Evelyn Warner

photanol cyanobacteria platform synbio bioplastics

News and Trends 12 Dec 2016

Meet Photanol: Harnessing Cyanobacteria’s Powers for Green Chemicals

Producing fuels and chemicals from CO2 and light has long been a dream of Biotech, and Amsterdam-based Photanol is working on making it an industrial reality with engineered cyanobacteria. I had a chat with Ross Gordon, Director of Business Development, about Photanol’s strategy. Photanol was present at the latest European Bioplastics Conference to present how it uses cyanobacteria, […]

December 12, 2016 - 3 minutesmins - By Denise Neves Gameiro

LeStudio

News and Trends 12 Dec 2016

A New Antibiotic from Your Nose! Thanks to Functional Genomics

Could your nose lead to major discoveries in antibiotic production? Genome mining of nose bacteria has revealed a new powerful antibiotic. Functional genomics offers a powerful tool for the isolation and detection of novel antibiotics, as the data obtained from it can be used to describe gene functions and interactions. The human microbiome has been largely […]

December 12, 2016 - 2 minutesmins - By Joachim Eeckhout

MinIOn 5 0

News and Trends 12 Dec 2016

With a new €120M Infusion, Pocket NGS CEO talks Success and Strategy

Seeking to disrupt the NGS market, Oxford Nanopore is rolling in cash. Before we heard the news, we sat down with CEO Gordon Sanghera to talk about the company’s success. December has been a stellar month for Oxford Nanopore. Just over a week ago, Oxford Nanopore’s MinION device was used to sequence the whole genome of a number […]

December 12, 2016 - 9 minutesmins - By Evelyn Warner

ADVERTISEMENT

Screenshot 2016 12 08 at 5.09.55 PM e1481213471552

News and Trends 9 Dec 2016

Paris takes the lead in Digital Health for Diabetes Type 2

The smell of freshly baked baguettes and good news from the capital have brought us this week to France. Voluntis has received market approval for a device that could change the life of millions of people with diabetes type 2, check out this cool company! City: Paris, France Founded: 2001 Employees: 100 Financial data: Total of €29.8M raised in […]

December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 518493754

News and Trends 9 Dec 2016

Galapagos gets another Milestone Payment from Gilead

Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […]

December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 381468874

News and Trends 9 Dec 2016

Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […]

December 9, 2016 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 12 08 at 4.52.00 PM e1481212500410

News and Trends 9 Dec 2016

Our Startup Battle Winner uses CRISPR in a Whole New Way

Eligo Bioscience came out on top in the Startup Battle at Labiotech Refresh, watch the founder’s pitch to see how! CRISPR can be used to cut and replace virtually any gene, which has fueled a fierce patent battle over the rights to use it for gene therapy in humans. Eligo Bioscience, however, focuses on using this powerful tool to […]

December 9, 2016 - 1 minutemin - By Clara Rodríguez Fernández

Melpomene

News and Trends 9 Dec 2016

Lifting the Chemo Fog: Virtual Reality has Medical Applications!

Cancer can make life unbearable for some patients, but sometimes the treatment only adds to the pain. Could virtual reality treatments improve their lives? The vast majority of modern cancer therapies are focused on halting the progression and the spread of the disease to save the patient’s life. These treatments are usually aggressive, and approximately […]

December 9, 2016 - 3 minutesmins - By Ekaterina Perets

20277338488 8cdc61e570 k e1481207967565

News and Trends 8 Dec 2016

Meet the Newest ALS Pioneer Company from Switzerland

AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. […]

December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT